Cure Rare Disease (CRD), a nonprofit biotechnology organization headquartered in Woodbridge, Connecticut, and the LGMD2L Foundation, a patient advocacy group based in Park Ridge, Illinois, have entered a multi-year partnership to develop a gene replacement therapy for Anoctamin 5 (ANO5)-related disease, a rare genetic disorder also classified as limb-girdle muscular dystrophy type 2L (LGMD2L/R12). Under the agreement, the LGMD2L Foundation has committed USD 7.65 million to fund the program from initial therapeutic design through to a first-in-human clinical trial. No territorial restrictions or licensing rights were disclosed, consistent with the nonprofit structure of both organizations. The deal represents CRD’s first program targeting ANO5-related disease and the LGMD2L Foundation’s largest known research funding commitment to date.
Anoctamin 5 gene therapy: mechanism and disease rationale
ANO5-related disease is caused by loss-of-function mutations in the ANO5 gene, which encodes a calcium-activated chloride channel protein involved in muscle membrane repair. Patients with LGMD2L/R12 experience progressive weakness in the proximal muscles of the shoulders, upper arms, and thighs, with healthy muscle tissue gradually replaced by fat and scar tissue. The condition is autosomal recessive, and a founder mutation in ANO5 has been identified as a major cause of limb-girdle muscular dystrophy in Northern European populations.
The therapy under development is a gene replacement approach delivered via a next-generation adeno-associated virus (AAV) capsid, designed to introduce a functional copy of the ANO5 gene into affected muscle cells. CRD has stated that its next-generation capsid technology has the potential to offer an improved safety profile compared to first-generation AAV vectors. The same capsid platform underpins two additional gene replacement programs in CRD’s pipeline targeting LGMD2i/R9 and LGMD2g/R7. There are currently no approved disease-modifying treatments for LGMD2L/R12. Standard of care is limited to supportive management including physical therapy and orthopedic interventions. There are no publicly available records of clinical trials for other ANO5-targeted gene therapies at present.